Louis Pasquale, MD
Glaucoma Specialist · New York, NYNPI 1154311249
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 76.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,280 and has fallen 93.9% since, to $78 in 2025. That places this record below the midpoint for glaucoma specialist clinicians in NY, where the typical reported total is $2,507.
Across 17 payments — averaging $119.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Aerie Pharmaceuticals, Inc.$227
- Alcon$125
- Glaukos Corporation$59
- Bausch & Lomb Americas Inc.$55
- Carl Zeiss Meditec AG$19
What the payments were for
- Consulting fees$1,20059%
- Food & beverage$78639%
- Education$181%
- Gifts$191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $1,537 |
| Aerie Pharmaceuticals, Inc. | 2 | $227 |
| Alcon | 4 | $125 |
| Glaukos Corporation | 1 | $59 |
| Bausch & Lomb Americas Inc. | 3 | $55 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$1,430
How this compares
$2,023 in reported general payments places this provider in the 30th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 73 | $42,132 |
| VyzultaLatanoprostene Bunod | 82 | $39,715 |
| LumiganBimatoprost | 67 | $30,894 |
| RhopressaNetarsudil Mesylate | 46 | $27,807 |
| Brimonidine Tartrate | 213 | $24,324 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 75 | $15,280 |
| RestasisCyclosporine | 31 | $13,850 |
| XiidraLifitegrast | 15 | $9,848 |
| Brinzolamide | 40 | $7,935 |
| Latanoprost | 768 | $6,626 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,444 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $5,253 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 288 | $5,211 |
| Travoprost | 18 | $4,674 |
| Pilocarpine Hcl | 56 | $2,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $227 | $69,938119 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $55 | $49,56397 claims |
| AlconSimbrinza | $125 | $15,28075 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in New York
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Sonya DharNew York$19K
- Yvonne OkakaNew York$5K
- Varun ReddyNew York$4K
- Eileen ChangNew York$3K
- Paul PetrakosNew York$3K
- Gerald SheppsNew York$3K
- Nehali NantiNew York$2K
- Johnny LiNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.